Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation reports developments across medical technology, patient monitoring and connected care. Company updates commonly center on Masimo SET pulse oximetry, noninvasive measurements, sensors, patient monitors, Masimo Hospital Automation and Masimo SafetyNet platforms, and telehealth or telemonitoring applications used in hospital and care settings.
Recurring MASI news also includes clinical evidence for monitoring performance, operating and financial results, non-GAAP financial materials, material agreements, shareholder voting matters, governance updates and capital-structure disclosures. The company’s public updates reflect its focus on healthcare monitoring technologies following the completed disposition of its consumer audio business.
Masimo (NASDAQ: MASI) announced its participation in the 44th Annual Raymond James Institutional Investors Conference on March 7, 2023, at 11:00 a.m. Eastern Time. Investors can access a live webcast of the presentation on the Masimo website, with a replay available afterward.
Masimo is a leading global medical technology company known for its innovative monitoring solutions, including the Masimo SET®, which has been shown to outperform other pulse oximetry technologies. The company aims to enhance patient outcomes and reduce healthcare costs through its advanced technologies.
Masimo reported strong financial results for Q4 and full-year 2022, with consolidated revenue reaching $617 million and $2,035.8 million respectively. The healthcare revenue was $351.9 million in Q4, growing 7.4% year-over-year, while full-year healthcare revenue hit $1,340.3 million with 8.2% growth. Non-healthcare revenue for Q4 was $265.1 million. The company achieved a GAAP net income of $41.1 million in Q4, or $0.76 per diluted share. For 2023, Masimo projects consolidated revenue between $2,415 million and $2,460 million, indicating continued growth.
Masimo (NASDAQ: MASI) announced findings from a study published in Medicine, showing that using the Oxygen Reserve Index (ORi™) alongside standard SpO2 monitoring effectively reduced intraoperative hyperoxemia during laparoscopic gastrectomy. Conducted by Dr. Jin Hee Ahn and team, the study demonstrated significant differences in arterial oxygen levels; the SpO2 group had a higher PaO2 compared to the ORi-SpO2 group one hour post-surgery (250.31 mmHg vs. 170.07 mmHg, p .001). The severe hyperoxemia incidence was lower in the ORi-SpO
Masimo (NASDAQ: MASI) announced that its Centroid wearable, wireless patient position and activity sensor received an Innovative Technology designation from Vizient, Inc., aimed at improving healthcare practices. Centroid helps prevent hospital-acquired pressure injuries (HAPIs), which affect 2.5 million patients annually in the U.S., with nearly 60,000 fatalities each year. It monitors patient position and movements using Bluetooth technology and integrates with the Masimo Root Patient Monitoring platform.
This recognition positions Masimo for potential growth in healthcare solutions, illustrating its commitment to enhancing patient outcomes and lowering care costs.
Masimo (NASDAQ: MASI) will announce its fourth quarter and FY 2022 financial results on February 28, 2023, after market closure. The results will be reviewed in a conference call at 1:30 p.m. PT (4:30 p.m. ET), hosted by CEO Joe Kiani and CFO Micah Young. Participants must register to obtain the dial-in details. Masimo specializes in medical technology, focusing on noninvasive monitoring solutions to enhance patient outcomes and reduce care costs. Their innovations include pulse oximetry and various blood monitoring technologies, widely used in leading healthcare institutions globally.
Masimo (NASDAQ: MASI) has launched the Visual Clinical Activity Monitoring (VCAM™), an AI-based video analysis system designed to enhance compliance with hand hygiene protocols in hospitals. The VCAM integrates with Masimo Hospital Automation™ solutions, providing real-time notifications and analytics to improve hygiene adherence and reduce hospital-acquired infections (HAIs). A Finnish study indicates a direct correlation between hand hygiene compliance and lower HAI rates. The system tracks handwashing and sanitization activities, offering actionable insights for healthcare facilities.
Masimo (NASDAQ: MASI) announced results from a study showing that maintaining higher end-tidal carbon dioxide (EtCO2) levels enhances cerebral oxygenation during video-assisted thoracoscopic surgery (VATS). Conducted by researchers from Tanta University and The King Fahd General Hospital, the research revealed significant improvements in regional cerebral oxygenation and postoperative cognitive function, with better Aldrete and mini mental status exam (MMSE) scores among patients with higher EtCO2 (39-45 mmHg) compared to lower levels (32-38 mmHg). The study involved 70 patients and utilized the Masimo Root® monitoring platform to track multiple physiological parameters.
Masimo (NASDAQ: MASI) and Royal Philips (NYSE: PHG) have announced an expansion of their partnership to enhance patient monitoring for home telehealth applications with the Masimo W1™ watch. This innovative technology will integrate Masimo's advanced health tracking with Philips's patient monitoring ecosystem, offering continuous, remote monitoring of vital health data. The combined solution aims to support early discharge initiatives and chronic illness management. The Masimo W1 is CE marked and awaiting FDA clearance. This development will be showcased at Arab Health 2023, highlighting advancements in telehealth.
A U.S. Administrative Law Judge ruled that Apple Inc. (AAPL) violated the Tariff Act by importing and selling Apple Watches with pulse oximetry technology infringing Masimo's (MASI) patents. The case revolves around the pulse oximeter functionality first introduced in the Apple Watch Series 6. The U.S. International Trade Commission will now decide on a potential import ban. This ruling raises concerns about Apple's practices regarding technology innovation and could influence market accountability.
Masimo (NASDAQ: MASI) announced a study showing that its SpHb® noninvasive hemoglobin measurement demonstrated "acceptable accuracy and excellent correlation" with invasive laboratory tests. Conducted on 650 emergency department patients, the study highlighted the quick and cost-effective benefits of SpHb, with a Pearson correlation coefficient of 0.812. While the results suggest SpHb can assist in clinical decisions, it is not intended as a substitute for standard laboratory tests. Further research is needed to assess its impact on patient outcomes.